NCT03523039View on ClinicalTrials.gov

Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

March 1, 2022

Conditions
Cardiac Arrest
Interventions
DEVICE

CytoSorb® Hemoadsorption

The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.

Trial Locations (1)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT03523039 - Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome | Biotech Hunter | Biotech Hunter